Literature DB >> 24682740

Detection of serum p53 antibodies from Chinese patients with papillary thyroid carcinoma using phage-SP-ELISA: correlation with clinical parameters.

Pengtao Pan1, Xiaoyi Han, Fangqian Li, Qingfeng Fu, Xiang Gao, Hui Sun, Li Wang.   

Abstract

The goal of the present study was to investigate whether p53 antibodies (Abs) could be a relevant marker for papillary thyroid carcinoma (PTC). Three types of enzyme-linked immunosorbent assay (ELISA) methods were developed for the detection of p53 Abs, including p53-ELISA, phage-SS-ELISA, and phage-SP-ELISA. A total of 304 patients, including 117 cases with thyroid adenoma and 187 PTC patients, were enrolled in this study. Expression of p53 protein and mutation in BRAF gene were evaluated in paraffin-embedded tissue from 44 patients with PTC, in order to elucidate their correlations with the presence of p53 Abs. Compared with p53-ELISA and phage-SS-ELISA, phage-SP-ELISA presented the highest detection efficiency of p53 Abs in patients with PTC, and a combination of these three ELISA systems could make the detection of p53 Abs more sensitive than using each of the individual ELISA methods. Furthermore, p53 Abs was positively associated with clinical stage (P = 0.044), node metastasis (P = 0.010), and p53 protein accumulation (P = 0.019). These results indicate that serum p53 Abs could be a useful marker for PTC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24682740     DOI: 10.1007/s12020-014-0243-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  33 in total

1.  Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India.

Authors:  R Ralhan; S Arora; T K Chattopadhyay; N K Shukla; M Mathur
Journal:  Int J Cancer       Date:  2000-03-15       Impact factor: 7.396

Review 2.  Diagnostic biomarkers of differentiated thyroid cancer.

Authors:  Tada Kunavisarut
Journal:  Endocrine       Date:  2013-05-04       Impact factor: 3.633

3.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

4.  Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients.

Authors:  R Tang; M C Ko; J Y Wang; C R Changchien; H H Chen; J S Chen; K C Hsu; J M Chiang; L L Hsieh
Journal:  Int J Cancer       Date:  2001-12-15       Impact factor: 7.396

5.  Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma.

Authors:  J Bourhis; R Lubin; B Roche; S Koscielny; J Bosq; I Dubois; M Talbot; P Marandas; G Schwaab; P Wibault; B Luboinski; F Eschwege; T Soussi
Journal:  J Natl Cancer Inst       Date:  1996-09-04       Impact factor: 13.506

6.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer.

Authors:  L V Crawford; D C Pim; R D Bulbrook
Journal:  Int J Cancer       Date:  1982-10-15       Impact factor: 7.396

Review 7.  Molecular diagnostics and predictors in thyroid cancer.

Authors:  Marina N Nikiforova; Yuri E Nikiforov
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

8.  Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface.

Authors:  R Lubin; B Schlichtholz; D Bengoufa; G Zalcman; J Trédaniel; A Hirsch; C Caron de Fromentel; C Preudhomme; P Fenaux; G Fournier; P Mangin; P Laurent-Puig; G Pelletier; M Schlumberger; F Desgrandchamps; A Le Duc; J P Peyrat; N Janin; B Bressac; T Soussi
Journal:  Cancer Res       Date:  1993-12-15       Impact factor: 12.701

9.  Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.

Authors:  Sunanda J Chatterjee; Ram Datar; David Youssefzadeh; Ben George; Peter J Goebell; John P Stein; Lillian Young; Shan-Rong Shi; Conway Gee; Susan Groshen; Donald G Skinner; Richard J Cote
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

10.  Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.

Authors:  P Lenner; F Wiklund; S O Emdin; C Arnerlöv; C Eklund; G Hallmans; H Zentgraf; J Dillner
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more
  1 in total

1.  Clinical significance of preoperative detection of serum p53 antibodies and BRAF(V600E) mutation in patients with papillary thyroid carcinoma.

Authors:  Qing-Feng Fu; Peng-Tao Pan; Le Zhou; Xiao-Li Liu; Feng Guo; Li Wang; Hui Sun
Journal:  Int J Clin Exp Med       Date:  2015-11-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.